Recurrent ovarian endometrioma after conservative surgery: A retrospective study

• 作者: Kuntima Kantawee Woraluk Somboonporn
• 来源期刊: 亚太生殖杂志（英文版）
• 年，卷（期）: 2022,（1）
• 所属期刊栏目: Original Articles
• 页码范围: 20-26
• 页数: 7页
• 语种: 英文
• DOI: 10.4103/2305-0500.335858

摘要

Objective: To study the prevalence and associated factors of recurrent ovarian endometrioma after ovarian cystectomy. Methods: This retrospective study analyzed 303 patients who underwent cystectomy for ovarian endometrioma and had at least a 2-year follow-up at Srinagarind Hospital from January 2013 to December 2018. The patients were divided into the recurrent and nonrecurrent groups according to the findings from postoperative transvaginal ultrasonography 6 months after undergoing surgery. Nineteen factors were collected for risk evaluation. The prevalence of recurrent ovarian endometrioma and its 95％ confident interval (CI) were calculated. Univariate and multivariable logistic regression analyses were performed to determine the association between factors and recurrence. Results: Recurrent ovarian endometrioma occurred in 33％ (95％ CI 27.7％-38.3％) patients. The median duration of follow-up was 36 months. during the median follow-up period of 36 months. Preoperative history of parity, preoperative infertility history, endometriosis surgery, moderate to severe dysmenorrhea, dyspareunia, intraoperative stage 4 according to revised American Society for Reproductive Medicine classification, presence of adenomyosis, and postoperative pain relief were associated factors based on univariate analysis. In contrast, infertility [odds ratio (OR) 2.22, 95％ CI 1.14-4.33], moderate to severe dysmenorrhea (OR 2.13, 95％ CI 1.09-4.15), and postoperative pelvic pain relief (OR 0.22, 95％ CI 0.12-0.42) were independently associated factors based on multivariable logistic regression analysis. Conclusions: In our setting, preoperative infertility history and moderate to severe dysmenorrhea were associated with a higher recurrent ovarian endometrioma risk. In contrast, postoperative pain relief was significantly associated with lower recurrence risk.